Price
No data yet.
Social Signal Score
Revenue
$592.8KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter Michael Collins
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 119
- Beta
- 0.41
- Country
- GB
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -31.15
Financials
Revenue
$592.8K+228.4%Net Income
$-2.68MEBITDA
$-2.12MFree Cash Flow
$-3.95MEPS (diluted)
$-0.00Shares Outstanding (diluted)
1.14B+1831.2%Operating Expenses
$2.48MCash & Debt
$2.85MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.35M | $-19.51M | $-0.06 |
| 2024 | $2.86M | $-14.22M | $-0.05 |
| 2023 | $2.19M | $-20.13M | $-0.08 |
| 2022 | $1.04M | $-21.69M | $-0.09 |
| 2021 | $1.01M | $-15.01M | $-0.07 |
| 2020 | $762.0K | $-11.61M | $-0.07 |
| 2019 | $871.5K | $-11.33M | $-0.07 |
| 2018 | $678.0K | $-8.94M | $-0.07 |
| 2017 | $628.0K | $-7.56M | $-0.08 |
| 2016 | $498.0K | $-6.57M | $-0.09 |
| 2015 | $361.0K | $-4.89M | $-0.08 |
| 2014 | $0.00 | $-3.59M | $-0.08 |
| 2013 | $801.0K | $-1.06M | $-0.02 |
| 2012 | $969.0K | $-865.7K | $-0.02 |
Valuation
ANPCFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
140+366.67%Social Signal Score
Mentions (4)
- Newsproactiveinvestors.com·6h ago·Neutral
CelLBxHealth looking up as it bolsters commercial pipeline CelLBxHealth PLC (AIM:CLBX, FRA:DWV) told investors it is targeting revenues of £3 million to £4 million in 2027, potentially more than doubling its expected 2026 turnover, as new pharmaceutical contracts begin to bolster its commercial pipeline. The cancer diagnostics specialist said third-quarter new business tripled to £300,000 from £100,000 a year earlier, with a further £100,000 secured in early October.
View source ↗ - Newsproactiveinvestors.com·6h ago·Negative
CelLBxHealth lands contract with Swiss biotech for clinical study CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has secured an agreement with a Swiss biotechnology company to support a radiopharmaceutical clinical study, extending the use of its circulating tumour cell (CTC) technology into targeted cancer treatment research. The company has signed a Master Services Agreement and accompanying Statement of Work covering a programme that will combine its CTC enrichment and analysis capabilities with the Sw
View source ↗ - Newsproactiveinvestors.com·7d ago·Neutral
Cellbxhealth signs new statement of work with US pharma company CelLBxHealth PLC (AIM:CLBX, FRA:DWV), which develops technology to collect tumour cells from blood, has signed a new statement of work worth around $65,000 with an existing US pharmaceutical customer. The agreement covers processing around 100 patient samples using its Parsortix platform to isolate and collect circulating tumour cells for molecular analysis, including mRNA analysis.
View source ↗ - Newsproactiveinvestors.co.uk·70d ago·Negative
CelLBxHealth's blood test spots hard-to-detect cells from brain tumours An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company. Glioblastoma rarely spreads beyond the brain, which had made blood-based detection of the disease an unlikely prospect.
View source ↗
Earnings
Thu, Apr 29(in 6 months)
Typical surprise +93.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jun 22$-0.00 vs $-0.03beat
Estimates and results for ANPCF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ANPCF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.